Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.44 |
| ▸ | LPL | P06858 | 7/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16239386 | 0.89 | DGAT1 (0.49) | DGAT1LIPGLPLEGFRHTR1A | |
| SCHEMBL17474563 | 0.87 | DGAT1 (0.54) | DGAT1LIPGLPLEGFRNPC1 | |
| SCHEMBL3767677 | 0.84 | DGAT1 (0.52) | DGAT1LIPGLPLEGFRSMN1; SMN2 | |
| SCHEMBL24094217 | 0.84 | LPL (0.44) | DGAT1LIPGLPLHIF1AMAPT | |
| SCHEMBL28738862 | 0.83 | DGAT1 (0.51) | DGAT1LIPGLPLEGFRNPC1 | |
| SCHEMBL182480 | 0.83 | DGAT1 (0.51) | DGAT1LIPGLPLEGFRHTR1A | |
| SCHEMBL16336555 | 0.83 | DGAT1 (0.51) | DGAT1LIPGLPLEGFRMAPT | |
| SCHEMBL15884409 | 0.83 | EGFR (0.52) | DGAT1LIPGLPLEGFRHTR1A | |
| SCHEMBL24058035 | 0.83 | DGAT1 (0.51) | DGAT1LIPGLPLEGFRMAPT | |
| SCHEMBL31750228 | 0.83 | DGAT1 (0.51) | DGAT1LIPGLPLHIF1AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022122780-A1 | LIQUID CRYSTAL MIXTURE AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2022-06-16 | — | — | WO | disclosed |
| EP-2435436-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8354422-B2 | Pyrimidine inhibitors of kinase activity | ABBOTT LABORATORIES INC. (US) | 2013-01-15 | — | — | US | disclosed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | IGF1R, CDK2, TK1 | DGAT1 3934/4885LIPG 4067/4885LPL 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.